Company Response to Exchange Query on Financial Results
Date and Nature of Exchange Communication
Anthem Biosciences Limited received a query from the National Stock Exchange of India Limited (NSE) via email dated June 17, 2026. The query pertained to certain discrepancies identified in the Financial Results for the Quarter and Year ended March 31, 2026, which were originally submitted to the exchange on May 19, 2026.
Clarification on Trading Volume and Financial Results
The company's clarification, dated June 23, 2026, addressed two specific points raised by the exchange:
- Mismatch in Yearly PAT Figures: The company clarified that there was no discrepancy in the Profit After Tax (PAT) figure for the Financial Year 2025-26. The PAT of INR 5,917.92 million was consistently reported in both the PDF version of the financial statement and the XBRL filing.
- Non-disclosure of Consolidated EPS in XBRL: The company stated that the omission of the Consolidated Earnings Per Share (EPS) from the XBRL filing was the result of an inadvertent clerical error during the filing process. The company emphasized that this omission was unintentional and did not affect any other financial information disclosed.
Regulatory Compliance and Corrective Action
The company confirmed its commitment to regulatory compliance. It stated it would immediately submit a revised XBRL filing to the Stock Exchange to incorporate the Consolidated Earnings Per Share (EPS) after the submission of this clarification letter. The letter was signed by Divya Prasad, Company Secretary & Compliance Officer (Membership No: A41438), in her capacity as the compliance officer.